Project Grant R15HL177689
Award Date
1/15/25
Completion Date
12/31/27
Dollars Obligated
$458K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award of $734,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the key endothelial mechanisms that direct hematopoietic stem cells (HSCs) across the blood vessel wall and into their niche. The research, conducted by Boston Medical Center Corporation, will use high-resolution live cell imaging, structure-function studies, and in vivo proximity-dependent biotinylation in zebrafish to define the endothelial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,276,908 in funding to Bloodworks (Puget Sound Blood Center and Program) from March 1, 2025 to February 28, 2032. The grant supports advanced molecular and translational research on the mechanisms of von Willebrand disease and sickle cell disease, which both involve the von Willebrand factor protein. The research aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $296,892 to support research aimed at understanding the molecular regulation of lymphoid lineage priming in both steady state and regenerative hematopoiesis. The research, conducted by The Children's Hospital Corporation (Boston Children's Hospital), will use single-cell sequencing and lineage tracing approaches to elucidate how the transcription factor TCF15...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $295,438 to the University of Florida to develop a novel ex vivo expansion platform for human hematopoietic stem cells (HSCs). The goal is to significantly increase the availability of suitable HSC donors for hematopoietic stem cell transplantation and improve post-transplant recovery, which is critical for treating life-threatening blood and bone marrow...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the Trustees of Indiana University, Indianapolis provides $792,498 to investigate the regulation of hematopoietic stem cells (HSCs) under low oxygen tension (hypoxia). The research aims to understand the signaling and metabolic alterations in HSCs under hypoxic conditions and explore the potential to manipulate these processes in normoxic conditions to improve HSC...
This federal Project Grant award for $657,368.00, issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the mechanisms controlling microRNA (miRNA) processing and degradation pathways during hematopoietic development. The primary awardee, The Washington University, will utilize human pluripotent stem cell lines with mutations in miRNA deadenylases and exosome components to identify novel...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $802,301 to Weill Medical College of Cornell University to conduct research on controlling the stem cell niche to mitigate the risks of clonal hematopoiesis, a condition that affects over 7 million people in the U.S. and increases their risk for life-shortening diseases. The research aims to define the mechanisms that switch the stem cell niche on and off,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Albert Einstein College of Medicine. The grant, awarded on July 9, 2025, will fund research to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis in zebrafish and human induced pluripotent stem cells. The project aims to provide mechanistic insights into how these co-occurring mutations contribute to the...
The federal Project Grant award K99HL171844, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to mechanistically understand the role of the WNK1 kinase in regulating myeloid progenitor fate and the shift towards emergency granulopoiesis during infection. The $125,431 award, spanning from September 1, 2024 to August 31, 2026, will enable the awardee at the Sloan-Kettering Institute for Cancer...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,209 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The goal of this 4-year project, starting May 1, 2025, is to develop and evaluate targeted nanoparticles for in vivo hematopoietic stem cell gene therapy to treat genetic blood diseases and disorders. Key objectives include optimizing nanoparticle formulations loaded with gene editing...